一分钟看懂
这是一项关于肺癌的III 期研究，登记的药物或干预包括AZD9291 80 mg/40 mg；Placebo AZD9291 80 mg/40 mg；Open-label AZD9291 80 mg/40 mg，当前状态为研究进行中，已停止招募。登记地点显示中国北京、长春、大连、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
AZD9291 80 mg/40 mg；Placebo AZD9291 80 mg/40 mg；Open-label AZD9291 80 mg/40 mg · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Research Site · 北京
- Research Site · 长春
- Research Site · 大连
- Research Site · 广州
- Research Site · 杭州
- Research Site · 昆明
- Research Site · 南京
- Research Site · 南宁
- Research Site · 上海
- Research Site · 沈阳
- Research Site · 苏州
- Research Site · 天津
- Research Site · 乌鲁木齐
- Research Site · 西安
- Research Site · 厦门
- Research Site · 扬州
- Research Site · 郑州
公开的入选条件
- 1. Male or female, aged at least 18 years.
- 2. Histologically confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histology
- 3. MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care.
- 4. Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria.
- 5. Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.
- 6. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
- 7. Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization.
- 8. World Health Organization Performance Status of 0 to 1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT02511106；登记信息更新于 2026-09-11。